Press Releases

Genocea to Present at Two October Investor Conferences

September 24, 2018 at 8:02 AM EDT

CAMBRIDGE, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that Chip Clark, president and chief executive officer, will present a corporate overview at two upcoming investor conferences:

  • Cantor Global Healthcare Conference
    • Monday, October 1, 2018 at 7:45am ET in New York, New York
  • Ladenburg 4th Annual Healthcare Conference
    • Tuesday, October 2, 2018 at 11:30am ET in New York, New York

The live webcasts of both presentations can be accessed by visiting the "Events and Presentations" tab of the investor relations section of the Genocea website at Replays of the webcasts will be archived for 90 days following the conferences.

About Genocea Biosciences, Inc.
Genocea's mission is to help conquer cancer by designing and delivering targeted cancer vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea is currently studying the safety, immunogenicity, and efficacy of its lead neoantigen cancer vaccine, GEN-009, in a Phase 1/2a clinical trial. For more information, please visit

Jennifer LaVin

Genocea Logo_RGB.jpg

Source: Genocea Biosciences, Inc.